Research Analysts’ Weekly Ratings Updates for Edwards Lifesciences (EW)

A number of firms have modified their ratings and price targets on shares of Edwards Lifesciences (NYSE: EW) recently:

• 8/7/2025 – Edwards Lifesciences had its price target raised by analysts at Wells Fargo & Company from $84.00 to $88.00. They now have an “overweight” rating on the stock.
• 7/29/2025 – Edwards Lifesciences was upgraded by analysts at Daiwa America from a “hold” rating to a “strong-buy” rating.
• 7/29/2025 – Edwards Lifesciences was upgraded by analysts at BTIG Research from a “neutral” rating to a “buy” rating. They now have a $100.00 price target on the stock.
• 7/26/2025 – Edwards Lifesciences was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating.
• 7/25/2025 – Edwards Lifesciences had its “buy” rating reaffirmed by analysts at The Goldman Sachs Group, Inc..
• 7/25/2025 – Edwards Lifesciences was upgraded by analysts at William Blair to a “strong-buy” rating.
• 7/25/2025 – Edwards Lifesciences had its price target raised by analysts at Piper Sandler from $83.00 to $90.00. They now have an “overweight” rating on the stock.
• 7/25/2025 – Edwards Lifesciences had its price target raised by analysts at Barclays PLC from $90.00 to $95.00. They now have an “overweight” rating on the stock.
• 7/25/2025 – Edwards Lifesciences had its price target raised by analysts at Wells Fargo & Company from $80.00 to $84.00. They now have an “overweight” rating on the stock.
• 7/25/2025 – Edwards Lifesciences had its price target raised by analysts at Mizuho from $87.00 to $95.00. They now have an “outperform” rating on the stock.
• 7/25/2025 – Edwards Lifesciences had its price target raised by analysts at Royal Bank Of Canada from $85.00 to $89.00. They now have an “outperform” rating on the stock.
• 7/25/2025 – Edwards Lifesciences had its price target raised by analysts at JPMorgan Chase & Co. from $80.00 to $85.00. They now have a “neutral” rating on the stock.
• 7/25/2025 – Edwards Lifesciences had its price target raised by analysts at Robert W. Baird from $78.00 to $79.00. They now have a “neutral” rating on the stock.
• 7/25/2025 – Edwards Lifesciences had its price target raised by analysts at Evercore ISI from $77.00 to $80.00. They now have an “in-line” rating on the stock.
• 7/25/2025 – Edwards Lifesciences had its price target raised by analysts at Canaccord Genuity Group Inc. from $75.00 to $81.00. They now have a “hold” rating on the stock.
• 7/25/2025 – Edwards Lifesciences had its price target raised by analysts at Truist Financial Corporation from $81.00 to $82.00. They now have a “hold” rating on the stock.
• 7/25/2025 – Edwards Lifesciences had its price target raised by analysts at Stifel Nicolaus from $90.00 to $95.00. They now have a “buy” rating on the stock.
• 7/25/2025 – Edwards Lifesciences had its price target raised by analysts at Deutsche Bank Aktiengesellschaft from $85.00 to $94.00. They now have a “buy” rating on the stock.
• 7/16/2025 – Edwards Lifesciences had its price target raised by analysts at Mizuho from $85.00 to $87.00. They now have an “outperform” rating on the stock.
• 7/15/2025 – Edwards Lifesciences had its price target raised by analysts at Morgan Stanley from $75.00 to $81.00. They now have an “equal weight” rating on the stock.
• 7/10/2025 – Edwards Lifesciences was upgraded by analysts at Argus to a “strong-buy” rating.
• 7/8/2025 – Edwards Lifesciences had its price target raised by analysts at Evercore ISI from $73.00 to $77.00. They now have an “in-line” rating on the stock.

Edwards Lifesciences Stock Down 0.2%

EW stock opened at $78.23 on Tuesday. Edwards Lifesciences Corporation has a 52 week low of $64.00 and a 52 week high of $83.00. The company has a market capitalization of $45.93 billion, a price-to-earnings ratio of 11.26, a price-to-earnings-growth ratio of 3.78 and a beta of 1.08. The firm’s 50-day moving average is $77.12 and its two-hundred day moving average is $74.24. The company has a current ratio of 4.68, a quick ratio of 3.87 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Thursday, July 24th. The medical research company reported $0.67 EPS for the quarter, topping analysts’ consensus estimates of $0.62 by $0.05. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The company had revenue of $1.53 billion for the quarter, compared to the consensus estimate of $1.49 billion. During the same period in the previous year, the firm earned $0.70 EPS. Edwards Lifesciences’s revenue was up 11.9% on a year-over-year basis. On average, analysts forecast that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Insider Buying and Selling at Edwards Lifesciences

In other news, VP Daniel J. Lippis sold 4,114 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, July 28th. The shares were sold at an average price of $79.46, for a total value of $326,898.44. Following the transaction, the vice president owned 22,002 shares of the company’s stock, valued at $1,748,278.92. The trade was a 15.75% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, VP Donald E. Bobo, Jr. sold 2,570 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, June 2nd. The stock was sold at an average price of $77.40, for a total transaction of $198,918.00. Following the completion of the transaction, the vice president directly owned 50,356 shares in the company, valued at $3,897,554.40. This represents a 4.86% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 17,134 shares of company stock worth $1,311,745. 0.34% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Edwards Lifesciences

Several hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. grew its stake in shares of Edwards Lifesciences by 1.2% in the 2nd quarter. Vanguard Group Inc. now owns 69,997,629 shares of the medical research company’s stock worth $5,474,515,000 after purchasing an additional 798,801 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Edwards Lifesciences by 0.4% in the 2nd quarter. Geode Capital Management LLC now owns 12,722,416 shares of the medical research company’s stock worth $990,074,000 after purchasing an additional 45,555 shares during the last quarter. Jennison Associates LLC grew its stake in shares of Edwards Lifesciences by 15.7% in the 2nd quarter. Jennison Associates LLC now owns 11,670,991 shares of the medical research company’s stock worth $912,788,000 after purchasing an additional 1,584,958 shares during the last quarter. Brown Advisory Inc. increased its position in shares of Edwards Lifesciences by 7.6% in the fourth quarter. Brown Advisory Inc. now owns 8,155,355 shares of the medical research company’s stock worth $603,741,000 after acquiring an additional 575,699 shares in the last quarter. Finally, Deutsche Bank AG increased its position in shares of Edwards Lifesciences by 10.4% in the fourth quarter. Deutsche Bank AG now owns 6,903,202 shares of the medical research company’s stock worth $511,044,000 after acquiring an additional 652,923 shares in the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.